Maxcyte Stock Investor Sentiment

MXCT Stock  USD 3.34  0.09  2.62%   
Slightly above 62% of MaxCyte's investor base is looking to short. The analysis of overall sentiment of trading MaxCyte stock suggests that many investors are alarmed at this time. MaxCyte's investing sentiment can be driven by a variety of factors including economic data, MaxCyte's earnings reports, geopolitical events, and overall market trends.
  
over three months ago at www.macroaxis.com         
Disposition of 29767 shares by Erck Stanley C of MaxCyte at 0.04 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 17922 shares by Erck Stanley C of MaxCyte at 0.04 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
MaxCyte Director Executes Stock Options and Sells - TipRanks
Google News at Macroaxis
over six months ago at news.google.com         
MaxCyte director Johnston sells shares worth over 12,000 - Investing.com
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 3000 shares by Johnston John Joseph of MaxCyte at 2.926 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
MaxCyte shareholders have earned a 22 percent CAGR over the last five years - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
Price T Rowe Associates Inc. MD Has 106,000 Stake in MaxCyte, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
MaxCyte Stock Price Crosses Below 50-Day Moving Average of 345.70 - Defense World
Google News at Macroaxis
over six months ago at simplywall.st         
MaxCyte, Inc. Second-Quarter Results Heres What Analysts Are Forecasting For This Year
Simply Wall St News at Macroaxis
over six months ago at investorplace.com         
MXCT Stock Earnings MaxCyte Beats EPS, Beats Revenue for Q2 2024
sbwire news
over six months ago at investing.com         
Earnings call MaxCyte sees stable Q2 revenue, maintains cautious outlook
Investing News at Macroaxis
over six months ago at insidermonkey.com         
MaxCyte, Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over six months ago at finance.yahoo.com         
MaxCyte, Inc. Reports Q2 Loss, Tops Revenue Estimates
Yahoo News
over six months ago at gurufocus.com         
MaxCyte Inc Q2 2024 Earnings EPS of -0.09 Beats Estimates, Revenue Surges to 10.4 Million
Gurufocus Stories at Macroaxis
over six months ago at news.google.com         
Swedbank AB Invests 6.70 Million in MaxCyte, Inc. - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about MaxCyte that are available to investors today. That information is available publicly through MaxCyte media outlets and privately through word of mouth or via MaxCyte internal channels. However, regardless of the origin, that massive amount of MaxCyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MaxCyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MaxCyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MaxCyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MaxCyte alpha.

MaxCyte Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.